Related Experiment Video
Updated: Jul 3, 2026
08:04
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
Specific tyrosine kinase inhibitors regulate human osteosarcoma cells in vitro
Patrick J Messerschmitt1, Ashley N Rettew, Robert E Brookover
1Department of Orthopaedic Surgery, University Hospitals Case Medical Center, Case Western Reserve University, 11100 Euclid Avenue, 6th Floor Hanna House, Cleveland, OH 44118, USA. pmesserschmittmd@gmail.com
Clinical Orthopaedics and Related Research
|July 9, 2008
Summary
Targeted therapies using tyrosine kinase inhibitors show promise for osteosarcoma treatment. Specific inhibitors significantly reduced tumor cell motility, colony formation, and invasiveness, supporting their therapeutic potential.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Targeted therapies are crucial for treating various cancers, including osteosarcoma.
- Tyrosine kinases play a significant role in cancer cell proliferation and metastasis.
Purpose of the Study:
- To investigate the effect of specific tyrosine kinase inhibitors on human osteosarcoma cell lines.
- To determine if inhibiting tyrosine kinases can decrease osteosarcoma cell motility, colony formation, and invasiveness.
Main Methods:
- Utilized five human osteosarcoma cell lines (TE85, MNNG, 143B, SAOS-2, LM-7).
- Assessed the impact of Epidermal Growth Factor Receptor (EGF-R), Insulin-like Growth Factor 1 Receptor (IGF-1R), met, Janus Kinase (JAK), HER-2, Nerve Growth Factor Receptor (NGF-R), and Platelet-Derived Growth Factor Receptors (PDGF-Rs) inhibitors.
- Measured changes in cell motility, colony formation, and invasiveness.
Main Results:
- EGF-R inhibitor decreased motility in all tested cell lines (50-80%).
- IGF-1R and met inhibitors showed preferential reduction in motility in specific cell lines.
- EGF-R, IGF-1R, and met inhibitors significantly reduced colony formation (>80%) in TE85, MNNG, and 143B cells.
- EGF-R inhibitor reduced invasiveness in 143B cells by 62%.
- JAK inhibitor increased motility in SAOS-2 and LM7 cells.
Conclusions:
- Specific tyrosine kinases, including EGF-R, IGF-1R, and met, are critical regulators of osteosarcoma cell behavior.
- Targeting these kinases holds potential for developing novel osteosarcoma chemotherapies.
- Further research is warranted to explore the therapeutic efficacy of these inhibitors in osteosarcoma treatment.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:26Receptor Tyrosine Kinases
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...